Etomidate-Lipuro Special Precautions

Etomidate-Lipuro has been shown to be porphyrogenic in animal experiments and should therefore not be administered to patients with impaired biosynthesis of heme, unless the indication for administration of etomidate has been definitely established.
Etomidate-Lipuro may be used only by a doctor trained in endotracheal intubation and if equipment for artificial respiration is available.
Etomidate-Lipuro does not have analgesic efficacy. If used for short-term narcosis, a strong analgesic, e.g. fentanyl, must be given prior to or simultaneously with Etomidate-Lipuro; attention must be paid also to further information given under Interactions.
Use in Pregnancy and Lactation: Safety of the use of Etomidate-Lipuro during pregnancy has not been established. Therefore, Etomidate-Lipuro should be administered to pregnant women only exceptionally and if there is no alternative.
Etomidate is secreted into breast milk. If Etomidate-Lipuro must be given during the lactation period, nursing must be interrupted and not resumed before 24 hours after administration; breast milk secreted during this period must be discarded.